Takara Bio x Thermo Fisher Scientific Seminar on Advancing Viral Vector Production

Description

The viral vector market, which is crucial for vaccines and gene therapies, is experiencing rapid growth. Essential factors to produce viral vectors needed for clinical trials and commercial manufacturing include scalability in transitioning from process development to commercial production and the simplicity of operating the culture device. Thermo Fisher Scientific's ThermoScientific DynaDrive Single-Use Bioreactor (S.U.B.) is a versatile bioreactor that can cultivate cells used for AAV production across a wide range of volumes, from 50 L to 5,000 L.

In this seminar, representatives from both Takara Bio and Thermo Fisher Scientific, key players invigorating the gene therapy market, will explain the features of single-use bioreactors that enable mass manufacturing of AAV vectors. Additionally, they will present case studies with data that highlight the successful viral vector manufacturing process.

Speakers:

Hideto Chono, Ph.D. serves as the Deputy Head of CDM Business Development Division and General Manager at Takara Bio Inc. He holds a Ph.D. in Agriculture from Kyoto University and has been with Takara since 1992. He specializes in the research, development, and manufacturing of viral vectors, mRNAs, and engineered T-cells.

Hiroshi Nagasaki, Ph.D. is a Field Application Scientist at Thermo Fisher Scientific K.K. in Japan. With 13 years of experience at the company, Hiroshi leads a team of Field Application Scientists specializing in BioProduction. He holds a Ph.D. in agriculture from Nagoya University. Hiroshi's expertise and leadership have been instrumental in providing support to customers.